Impact of elevation of total bilirubin level and etiology of the liver disease on serum N-glycosylation patterns in mice and humans.
The GlycoFibroTest and GlycoCirrhoTest are noninvasive alternatives for liver biopsy that can be used as a follow-up tool for fibrosis patients and to diagnose cirrhotic patients, respectively. These tests are based on the altered N-glycosylation of total serum protein. Our aim was to investigate the impact of etiology on the alteration of N-glycosylation and whether other characteristics of liver patients could have an influence on N-glycosylation. In human liver patients, no specific alteration could be found to make a distinction according to etiological factor, although alcoholic patients had a significant higher mean value for the GlycoCirrhoTest. Undergalactosylation did not show a significantly different quantitative alteration in the cirrhotic and noncirrhotic population of all etiologies. Importantly, patients with an elevation of total bilirubin level (>2 mg/dl) had a strong increase of glycans modified with alpha1-6 fucose. The fucosylation index was therefore significantly higher in fibrosis/cirrhosis and hepatocellular carcinoma patients with elevated total bilirubin levels irrespective of etiology. Furthermore, in a multiple linear regression analysis, only markers for cholestasis significantly correlated with the fucosylation index. In mouse models of chronic liver disease, the fucosylation index was uniquely significantly increased in mice that were induced with a common bile duct ligation. Mice that were chronically injected with CCl(4) did not show this increase. Apart from this difference, common changes characteristic to fibrosis development in mice were observed. Finally, mice induced with a partial portal vein ligation did not show biological relevant changes indicating that portal hypertension does not contribute to the alteration of N-glycosylation.
Blomme
Bram
B
Dept. of Hepatology and Gastroenterology, Ghent Univ. Hospital, Belgium.
Van Steenkiste
Christophe
C
Vanhuysse
Jacques
J
Colle
Isabelle
I
Callewaert
Nico
N
Van Vlierberghe
Hans
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001663:Bilirubin / Q000097:blood*; D002240:Carbohydrate Sequence; D002252:Carbon Tetrachloride Poisoning / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000378:metabolism; D003135:Common Bile Duct; D005260:Female; D005643:Fucose / Q000378:metabolism*; D005690:Galactose / Q000378:metabolism; D006031:Glycosylation; D019694:Hepatitis B, Chronic / Q000097:blood; D019698:Hepatitis C, Chronic / Q000097:blood; D006801:Humans; D006975:Hypertension, Portal / Q000097:blood* / Q000378:metabolism; D008026:Ligation; D008103:Liver Cirrhosis / Q000097:blood* / Q000175:diagnosis; D008104:Liver Cirrhosis, Alcoholic / Q000097:blood*; D008107:Liver Diseases / Q000378:metabolism*; D008113:Liver Neoplasms / Q000097:blood* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008875:Middle Aged; D011134:Polysaccharides / Q000378:metabolism
D011134:Polysaccharides; D005643:Fucose; D001663:Bilirubin; D005690:Galactose